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Abstract
Background—Adjunctive behavioral smoking cessation treatments have the potential to improve
outcomes beyond standard care. The present study had two aims: 1) compare standard care (SC)
for smoking (four weeks of brief counseling and monitoring) to SC plus prize-based contingency
management (CM), involving the chance to earn prizes on days with demonstrated smoking
abstinence (carbon monoxide (CO) ≤6ppm); and 2) compare the relative efficacy of two prize
reinforcement schedules - one a traditional CM schedule, and the second an early enhanced CM
schedule providing greater reinforcement magnitude in the initial week of treatment but equal
overall reinforcement.
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Methods—Participants (N = 81 nicotine-dependent cigarette smokers) were randomly assigned
to one of the three conditions.
Results—Prize CM resulted in significant reductions in cigarette smoking relative to SC. These
reductions were not apparent at follow-up. We found no meaningful differences between the
traditional and enhanced CM conditions.
Conclusions—Our findings reveal that prize CM leads to significant reductions in smoking
during treatment relative to a control intervention, but the benefits did not extend long-term.
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Prize; contingency management; cigarette; tobacco; treatment efficacy
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1. INTRODUCTION
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Cigarette smoking results in 1 of every 5 deaths and extraordinary economic costs (Centers
for Disease Control and Prevention, 2008). Contingency management (CM) has
demonstrated efficacy for treating substance use disorders (Dutra et al., 2008; Prendergast et
al., 2006), including smoking (Ledgerwood, 2008 review). However, CM can be costly, with
reinforcement exceeding $1,000 (Higgins et al., 2004; Lamb et al., 2004). Petry and
colleagues developed a prize reinforcement program lower-cost by design, with
demonstrated efficacy with cocaine, opioid, alcohol and poly-substance-dependent patients
(e.g., Peirce et al., 2006; Petry et al., 2000; Petry et al., 2012). To date, one small, nonrandomized pilot has examined prize CM for smoking among substance abuse patients, with
prize CM engendering greater proportions of negative CO tests than standard care (Alessi et
al., 2008). The present study examines the efficacy of Prize CM for smoking in a
randomized trial.
A second purpose is to evaluate a scheduled increase in reinforcement magnitude early in
treatment. Reinforcement magnitude is a parameter that can increase treatment response
(Petry et al., 2004) and may thereby increase long-term abstinence (Kenford et al., 1994;
Higgins et al., 2006), but this has not yet been examined in a randomized clinical trial of
treatment-seeking smokers.
The two aims of the present study are: assess the efficacy of prize-based CM for cigarette
smoking; and compare a traditional versus early-treatment enhanced reinforcement schedule.

2. METHODS
Author Manuscript

2.1 Participants
Participants were nicotine-dependent smokers (N = 81) who responded to advertisements in
local newspapers, bulletin boards and at health fairs, and broadcast messages to staff of a
large health center and university. Inclusion criteria were: Fagerström Test of Nicotine
Dependence (Heatherton et al., 1991) score ≥4; age ≥18; and English literate. Exclusion
criteria were: uncontrolled psychiatric disorders (acute suicidality, psychosis); current
substance dependence excluding nicotine or caffeine; in recovery for pathological gambling;
or already receiving smoking treatment. Recruitment occurred December 2007 to January
2011.
2.2 Procedures
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Individuals were screened for eligibility and scheduled for intake if appropriate. During
intake, written informed consent and self-report assessments and CO and urine cotinine tests
were completed.
After Intake, participants attended the clinic twice daily (separated by 5+ hours) MondayFriday for 5 weeks. Unexcused absences were considered positive CO readings; excused
absences (e.g., family emergency) were without consequences. Follow-up assessments
occurred 2- and 6-months after starting treatment, with $20 compensation per follow-up.
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2.3 Measures
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2.3.1—Demographic data were collected at intake. A brief screen of suicidality, psychosis
and substance abuse was adapted using the Structured Clinical Interview for the DSM-IVTR (First et al., 2002) to assess inclusion/exclusion. Pathological gambling was assessed
using the NORC-DSM Screen (Gerstein et al., 1999).
2.3.2—Smoking history included ages first smoked and smoked daily, and cigarettes
smoked daily.
2.3.3—Fagerström Test for Nicotine Dependence questionnaire assessed nicotine
dependence (Fagerstrom, 1978).
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2.3.4—Expired Carbon Monoxide (CO) levels were assessed at intake, twice daily during
baseline and treatment, and at follow-ups using an EC50-MP Micro CO monitor (Bedfont).
Levels ≤6ppm were considered smoking-negative for reinforcement purposes, consistent
with other studies (range: 4ppm–8ppm; Corby et al., 2000; Lamb et al., 2004).
2.3.5—Urinary Cotinine samples were collected at intake, Mondays weeks 2–5, and followups, and tested using the Accutest® NicAlertTM test-strip system (JANT Pharmacal
Corporation, Encino, CA). During treatment weeks 2–4, cotinine samples served as a
measure of weekend smoking abstinence (≤100ng/mL) to establish CM bonus draws.
2.4. Baseline
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All participants received $1 per sample, independent of results, with a $20 bonus for
submitting all 10 samples, to motivate compliance. Submitting ≥5 samples was required for
randomization, else individuals were discontinued and referred for treatment elsewhere.
The baseline phase allowed for assessment of smoking pre-treatment and time to prepare to
quit. On the last baseline visit, participants met with a research therapist to review a smoking
cessation self-help quit guide to prepare to quit (U.S. Public Health Service, June 2000).
Based on standards of care (Fiore et al., 2008), the materials emphasize motivation, social
support and behavioral skills to help reduce smoking.
Random assignment to one of the three treatment conditions and stratified by gender and any
CO ≤6 ppm during baseline (none or ≥1) occurred on treatment day 1 (quit date).
Statistician-prepared sequentially numbered randomization envelopes concealed group
assignments until assigned Randomization to CM conditions and standard treatment
occurred at a 2:1 ratio to ensure adequate power to compare the two CM conditions.
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2.5. Treatments
2.5.1. Standard care—Standard care (SC; weeks 2–5) involved monitoring CO and
cotinine, and brief counseling (Fiore et al., 2008). Participants received $1/sample regardless
of test results and a $20 weekly bonus for submitting all samples (maximum $120). Each
session, the therapist provided immediate feedback about CO/cotinine test results, briefly
(≈5 minutes) discussed recent smoking/abstinence, and praised quit efforts.
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2.5.2. Traditional prize CM—In addition to SC, traditional CM (TCM) patients earned
chances to win prizes for negative CO and cotinine samples (similar to Petry and Martin,
2002; Petry et al., 2000), with no compensation for compliance with only submitting
samples.
On treatment day 1, participants drew for a prize if CO was reduced at least 3ppm from
his/her intake level. Subsequently, draws were contingent on CO reading ≤6ppm. Draws
from the prize urn increased by 1 (up to 5) each consecutive day both daily CO tests met
criterion. CO levels >6 ppm, refusal to submit a sample, or unexcused absences reset draws
to one for the next negative sample.
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The TCM prize urn contained 250 slips of paper, with typical prize percentages (e.g., Petry
and Martin, 2002); 50% (125) did not result in prizes, 44.8% were Small (worth about $1,
e.g., snacks, toiletries); 4.8% were Large (worth about $20, e.g., gift certificates,
electronics); and 0.4% were Jumbo (worth $100, e.g., DVD players, gift certificates).
To reinforce weekend abstinence, each cotinine sample ≤100 ng/ml on Mondays resulted in
five bonus draws in weeks 3–5. Overall, 180 draws and 15 bonus draws were possible for
CO- and cotinine-negative tests, respectively.
2.5.3. Early-treatment enhanced prize reinforcement (ECM)—ECM participants
received SC, CO and cotinine monitoring and reinforcement criteria, described above.
Draws available and reinforcement criteria were identical to TCM, but the chance of
receiving reinforcement early in treatment was scheduled to be enhanced by providing
guaranteed prizes (100% probability, versus 50% chance in TCM) for negative CO tests
during treatment week 1.
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During week 1, the ECM urn included 91.2% Small, 8% Large and 0.8% Jumbo prizes. For
the remaining three weeks, an urn with 65.8% slips resulting in no prize, and 30% Small,
4% Large and 0.2% Jumbo prizes was used. Draws for cotinine-negative tests were made
from the urn with 100% winning slips, for the same overall reinforcement magnitude in both
CM conditions.
2.6. Analysis
We employed an intent-to-treat approach, including all participants who entered the
treatment phase. Analyses compared combined CM conditions versus SC, and TCM versus
ECM. Chi-square and t-tests were used to analyze baseline characteristics.
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Outcomes were average CO, longest duration of smoking abstinence (days; LDA), and
percent CO tests <4ppm. The CO criterion for reinforcement was ≤6ppm to maximize
opportunities for reinforcement, but CO <4ppm was used for analysis to ensure conservative
reporting of findings. A day of abstinence was defined as two consecutive CO tests <4ppm.
If sessions encompassed a weekend, the patient was considered abstinent for three
consecutive days if tests immediately before and after the weekend were negative.
Unexcused absences broke the string of abstinence, excused absences did not if preceded
and followed by negative samples.
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Linear mixed models were used to analyze group differences in CO levels baseline through
treatment. Fixed factors included treatment condition, time (50 testing sessions) and the
condition X time interaction. Cases were included as random-effects variables.
T-tests were used to assess LDA and attendance. LDA data were normalized using squareroot transformation for analysis, with raw data presented in tables to facilitate interpretation.
Percent negative CO was the number of CO tests <4ppm divided by number of treatment
sessions attended (maximum 40). Percent negative CO data and prize dollars earned could
not be transformed to normality so Mann-Whitney U tests were used. Analyses were re-run
using a cutoff of ≤6ppm (the reinforcement criterion). Although LDA and percent negative
were predictably higher than when we used the more stringent CO <4ppm, overall direction
and significance remained the same (available from first author).
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Chi-square analysis was used for group differences at follow-ups on 7-day point prevalence
(PPA; self-reported no smoking in the past 7 days and cotinine ≤100 ng/ml). Missing data
were analyzed as smoking-positive.

3. RESULTS
3.1. Demographics
See Supplemental Figure 1 for participant flow and Table 1 for demographic and baseline
data. CM participants had significantly more education than those in SC. Otherwise,
differences were nonsignificant (ps >.05). Overall, cigarettes per day ranged from 14.7 to
19.3 (p > .10) and average Fagerström scores revealed “moderate” nicotine dependence.
3.2. Standard Care versus CM
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Baseline CO levels were similar between CM and SC (Figure 1). Linear mixed model
analysis revealed a significant time X condition interaction, F(50,2860.37) = 2.71, p < .001,
with CM participants reducing CO levels over time relative to SC.
CM-treated participants demonstrated significantly greater LDA than SC patients (p < .05;
Table 1), with a medium effect size (d = .50). Percentage of negative CO tests was also
greater with CM than SC (p < .01; Table 1).
Participants attended an average (SD) of 87.8%(16.0%) of baseline and 70.3% (28.5%) of
treatment sessions, without differences between conditions (Table 1).
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Month 2 and 6 follow-up rates were 85% and 77%, respectively, without significant
differences between treatment conditions (ps >.10). CM and SC did not differ on PPA at 2month (6.3% vs. 0%; χ2(1, n = 81) = 1.12 p = .29) or 6-month follow-up (6.3% vs. 5.9%;
χ2(1, n = 81) = .00, p = .96).
3.3. Traditional versus Early-Enhanced CM
Linear mixed model analysis comparing TCM to ECM revealed a time main effect
(F(50,2193.12) = 25.77, p < .001), with CO levels decreasing over time regardless of
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condition. Neither the condition main effect nor time X condition interaction was significant
(p > .05; Figure 1).
TCM and ECM conditions did not differ significantly on LDA, percentage of CO-negative
test or attendance (Table 1), nor PPA at 2-months (10.7% vs. 2.8%; χ2(1, n = 64) = 1.69 p
= .19) or 6-month follow-up (10.7% vs. 2.8%; χ2(1, n = 64) = 1.69 p = .19).
3.4. Prize Earnings
Approximately 81% of CM participants earned prizes (median = $120.56). Differences in
earnings with TCM and ECM during week-1 or across the four weeks were nonsignificant
(Table 1).

4. DISCUSSION
Author Manuscript
Author Manuscript

Our findings demonstrate that prize CM is an efficacious smoking abstinence intervention,
consistent with research on money/voucher CM for smoking (Ledgerwood 2008), prize CM
for illicit substances (Petry et al., 2000; Petry et al., 2012), and Alessi et al’s (2008) pilot
study on prize CM for smoking. We found no significant differences in outcomes between
TCM and ECM. We thought that providing a schedule of increased chances of winning
prizes early in treatment would result in more abstinence initiation and subsequent
abstinence based on findings that higher magnitude of reinforcement results in better
outcomes (Petry et al., 2004). However, our data are more consistent with studies revealing
that start-up bonuses may not enhance CM effectiveness (Silverman et al., 1998). Indeed,
TCM LDA and percent negative were somewhat (but nonsignificantly) higher than ECM,
but CO levels during the week-1 enhanced period were comparable between conditions.
Furthermore, although the TCM and ECM were scheduled to have different initial
magnitudes, Table 1 demonstrates that in reality the early magnitude of reinforcement
actually received did not differ between groups.
Although CM facilitated greater smoking reductions during treatment, differences were not
apparent at follow-up. CM studies for smoking have primarily revealed no longer-term
benefits of CM (Ledgerwood, 2008). However, it is notable that high relapse rates are also
found for other efficacious smoking cessation interventions (Piasecki et al., 2002).
The present study has limitations. The sample size was relatively small. More importantly,
the treatment required an intense in-person visit schedule that would be difficult to sustain in
many populations (e.g., rural populations, low socioeconomic status).
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In summary, prize CM is efficacious in promoting initial smoking abstinence among
nicotine-dependent smokers. Research on methods to improve response rates and maintain
abstinence is needed.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Drug Alcohol Depend. Author manuscript; available in PMC 2016 September 13.

Ledgerwood et al.

Page 7

Author Manuscript

Acknowledgments
We thank Ken Bates, Lisa Sulkowski, Melissa Williams, Joi Moore, Caren Steinmiller, Debra Kish, Katie Linehan,
Bojana Knezevic, Ashley Wiedemann, Veeral Patel and the staff of the Psychiatric & Addiction Research Center for
their assistance on this project.

References

Author Manuscript
Author Manuscript
Author Manuscript

Alessi SM, Petry NM, Urso J. Contingency management promotes smoking reductions in residential
substance abuse patients. J Appl Behav Anal. 2008; 41:617–622. [PubMed: 19192865]
Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost,
and productivity losses – United States, 2000–2004. Morbidity and Mortality Weekly Report. 2008;
57(45):1226–1228. [PubMed: 19008791]
Corby EA, Roll JM, Ledgerwood DM, Schuster CR. Contingency management interventions for
treating the substance abuse of adolescents: A feasibility study. Exp Clin Psychopharmacol. 2000;
8:371–376. [PubMed: 10975628]
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of
psycosocial interventions for substance use disorders. Am J Psychiatry. 2008; 165:179–187.
[PubMed: 18198270]
Fagerstrom K-O. Measuring degree of physical dependence to tobacco smoking with reference to
individualization of treatment. Addict Behav. 1978; 3:235–241. [PubMed: 735910]
First, MB.; Gibbon, M.; Spitzer, RL.; Williams, JBW. The Structured Clinical Interview for DSM-IVTR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometrics
Research, New York State Psychiatric Institute; 2002.
Fiore, MC.; Jaen, CR.; Baker, TB.; Bailey, WC.; Benowitz, NL.; Curry, SJ., et al. Treating tobacco use
and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services,
Public Health Service; 2008.
Gerstein, D.; Murphy, S.; Toce, M.; Hoffmann, J.; Palmer, A.; Johnson, R., et al. Gambling impact and
behavior study. Chicago: University of Chicago; 1999.
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine
Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991; 86:1119–27.
[PubMed: 1932883]
Higgins ST, Heil SH, Dumeer AM, Thomas CS, Solomon LJ, Bernstein IM. Smoking status in the
initial weeks of quitting as a predictor of smoking-cessation outcomes in pregnant women. Drug
Alcohol Depend. 2006; 85:138–41. [PubMed: 16720082]
Higgins ST, Heil SH, Solomon LJ, Bernstein IM, Lussieur JP, Abel RL, Lynch E, Badger GJ. A pilot
study on voucher-based incentives to promote abstinence from cigarette smoking during pregnancy
and postpartum. Nicotine Tob Res. 2004; 6:1015–1020. [PubMed: 15801574]
Kenford SL, Fiore MC, Jorenby DE, Smith SS, Wetter D, Baker TB. Predicting smoking cessation.
Who will quit with and without the nicotine patch. JAMA. 1994; 271:589–94. [PubMed: 8301790]
Lamb RJ, Morral AR, Kirby KC, Iguchi MY, Galbicka G. Shaping smoking cessation using percentile
schedules. Drug Alcohol Depend. 2004; 76:247–259. [PubMed: 15561476]
Ledgerwood DM. Contingency management for smoking cessation: Where do we go from here? Curr.
Drug Abuse Rev. 2008; 1:340–349.
Peirce JM, Petry NM, Stitzer ML, Blaine J, Kellogg S, Satterfield F, Schwartz M, Krasnansky J,
Pencer E, Silva-Vazquez L, Kirby KC, Royer-Malvestuto C, Roll JM, Cohen A, Copersino M,
Kolodner K, Li R. Lower-cost incentives increase stimulant abstinence in methadone maintenance
treatment: A National Drug Abuse Treatment Clinical Trials Network study. Arch Gen Psychiatry.
2006; 63:201–208. [PubMed: 16461864]
Petry NM, Alessi SM, Ledgerwood DM. A randomized trial of contingency management delivered by
community therapists. J Consult Clin Psychol. 2012; 80:286–298. [PubMed: 22250852]
Petry NM, Martin B. Low-cost contingency management for treating cocaine- and opioid-abusing
methadone patients. J Consult Clin Psychol. 2002; 70:398–405. [PubMed: 11952198]

Drug Alcohol Depend. Author manuscript; available in PMC 2016 September 13.

Ledgerwood et al.

Page 8

Author Manuscript

Petry NM, Martin B, Cooney JL, Kranzler HR. Give them prizes and they will come: Contingency
management for treatment of alcohol dependence. J Consult Clin Psychol. 2000; 68:250–257.
[PubMed: 10780125]
Petry NM, Tedford J, Austin M, Nich C, Carroll KM, Rounsaville BJ. Prize reinforcement contingency
management for treating cocaine abusers: How low can we go, and with whom? Addiction. 2004;
99:349–360. [PubMed: 14982548]
Piasecki TM, Fiore MC, McCarthy DE, Baker TB. Have we lost our way? The need for dynamic
formulations of smoking relapse proneness. Addiction. 2002; 97:1093–1108. [PubMed: 12199822]
Prendergast M, Podus D, Finney J, Greenwell L, Roll JM. Contingency management for treatment of
substance use disorders: A meta-analysis. Addiction. 2006; 101:1546–1560. [PubMed: 17034434]
Silverman K, Wong CJ, Umbricht-Schneiter A, Montoya ID, Schuster CR, Preston KL. Broad
beneficial effects of cocaine abstinence reinforcement among methadone patients. J Consult Clin
Psychol. 1998; 66:811–824. [PubMed: 9803700]

Author Manuscript
Author Manuscript
Author Manuscript
Drug Alcohol Depend. Author manuscript; available in PMC 2016 September 13.

Ledgerwood et al.

Page 9

Author Manuscript
Author Manuscript

Figure 1.

Average twice-daily carbon monoxide levels (parts per million) for combined CM conditions
showed significant reductions relative to baseline and relative to Standard treatment (p < .
05). Traditional and Enhanced CM conditions did not differ from each other. (Note:
Traditional and Enhanced conditions are presented, but the combined CM condition is not,
to enhance the readability of the graph).
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